Isolated limb perfusion (ILP) therapy using a combination of tumour necrosis factor alpha (TNF) and cytostatic agents in hyperthermic conditions has proven to be effective in treating cancers limited to limbs or to a single organ such as the liver. A critical step for ILP is the accurate and real-time monitoring of systemic leakage with the aim of avoiding severe systemic TNF mediated toxicity. It has been established that TNF toxic effects become relevant when overcoming the 10% limit of the 'effective' therapeutic dose administered during ILP. The most diffuse procedure for systemic leakage monitoring is based on the utilization of human soluble serum albumin (HSA) labelled with I-131 and an external scintillation detector. In order to overcome some drawbacks connected with the properties of I-131, we developed a new procedure based on the utilization of HSA labelled with Tc-99m in combination with a hand held gamma probe used as a detector. Our procedure consists of the following steps: (1) a Tc-99m-HSA dose standardized as 0.5 MBq(.)kg(-1) body weight is injected into the ILP circuit before TNF administration; (2) a hand held gamma probe is placed over the pre-cordial area in a zone pre-marked on the patient's skin during a simulation test; (3) 48-72 h before ILP, a simulation test is obtained using a Tc-99m-HSA dose corresponding to 10% of the dose calculated for ILP (i.e., 0.05 MBq(.)kg(-1) body weight); (4) during the simulation test the maximum count-rate zone detected on the pre-cordial area is marked on patient's skin; (5) a 60 min time-activity curve corresponding to the circulating Tc-99m-HSA radioactivity effective decay is calculated and fitted; and (6) this time-activity curve is used to compensate for the leakage systemic counting observed during ILP. In order to compare the external, probe counting with the circulating radioactivity, in the first 10 patients from a total series of 43 treated patients, the results of external, probe monitoring were compared with the results of patient blood and perfusion circuit samples taken simultaneously every 5 min and measured by a laboratory gamma counter placed in the operating theatre. A good correlation was found between the two methods (R-2 = 0.965, P < 0.01). It is concluded that the proposed procedure, based on the combination of Tc-99m-HSA as the radiotracer and a hand held gamma probe as the detector, appears to be technically simple and accurate enough in the real-time monitoring of perfusion leakage in ILP cancer therapy. Moreover, using Tc-99m-HSA as the radiotracer, the risk of radioactive contamination is significantly lower in comparison with I-131-HSA.

Optimized procedure of real-time systemic leakage monitoring during isolated limb perfusion using a hand held gamma probe and 99mTc-HSA.

SCALERTA, ROMANO GABRIELE;FOLETTO, MIRTO;ROSSI, CARLO RICCARDO
2004

Abstract

Isolated limb perfusion (ILP) therapy using a combination of tumour necrosis factor alpha (TNF) and cytostatic agents in hyperthermic conditions has proven to be effective in treating cancers limited to limbs or to a single organ such as the liver. A critical step for ILP is the accurate and real-time monitoring of systemic leakage with the aim of avoiding severe systemic TNF mediated toxicity. It has been established that TNF toxic effects become relevant when overcoming the 10% limit of the 'effective' therapeutic dose administered during ILP. The most diffuse procedure for systemic leakage monitoring is based on the utilization of human soluble serum albumin (HSA) labelled with I-131 and an external scintillation detector. In order to overcome some drawbacks connected with the properties of I-131, we developed a new procedure based on the utilization of HSA labelled with Tc-99m in combination with a hand held gamma probe used as a detector. Our procedure consists of the following steps: (1) a Tc-99m-HSA dose standardized as 0.5 MBq(.)kg(-1) body weight is injected into the ILP circuit before TNF administration; (2) a hand held gamma probe is placed over the pre-cordial area in a zone pre-marked on the patient's skin during a simulation test; (3) 48-72 h before ILP, a simulation test is obtained using a Tc-99m-HSA dose corresponding to 10% of the dose calculated for ILP (i.e., 0.05 MBq(.)kg(-1) body weight); (4) during the simulation test the maximum count-rate zone detected on the pre-cordial area is marked on patient's skin; (5) a 60 min time-activity curve corresponding to the circulating Tc-99m-HSA radioactivity effective decay is calculated and fitted; and (6) this time-activity curve is used to compensate for the leakage systemic counting observed during ILP. In order to compare the external, probe counting with the circulating radioactivity, in the first 10 patients from a total series of 43 treated patients, the results of external, probe monitoring were compared with the results of patient blood and perfusion circuit samples taken simultaneously every 5 min and measured by a laboratory gamma counter placed in the operating theatre. A good correlation was found between the two methods (R-2 = 0.965, P < 0.01). It is concluded that the proposed procedure, based on the combination of Tc-99m-HSA as the radiotracer and a hand held gamma probe as the detector, appears to be technically simple and accurate enough in the real-time monitoring of perfusion leakage in ILP cancer therapy. Moreover, using Tc-99m-HSA as the radiotracer, the risk of radioactive contamination is significantly lower in comparison with I-131-HSA.
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11577/2461428
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 19
  • ???jsp.display-item.citation.isi??? ND
social impact